stockrow
Saturday 7 November 2026
Export NRXP’s income statement to Excel — free account
NRx Pharmaceuticals, Inc.
NRXP Healthcare Biotechnology
NRx Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 million.
- EPS
- +55.1%
- Free cash flow
- −142.6%
Quarter to June 2026, against a year earlier
2.34
0.07
+3.08%
Follow NRXP
Alert me
NRx Pharmaceuticals, Inc. (NRXP) P/E ratio
NRx Pharmaceuticals, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 409× (March 2019) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 409×
Ten-year median
0.0×
Current reading's percentile
80
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BDTX Black Diamond Therapeutics, Inc. compare | n/m |
| LENZ LENZ Therapeutics, Inc. compare | n/m |
| UNCY Unicycive Therapeutics, Inc. compare | n/m |
| IMUX Immunic, Inc. compare | n/m |
| AVXL Anavex Life Sciences Corp. compare | n/m |
| HURA TuHURA Biosciences, Inc. compare | n/m |
| PMVP PMV Pharmaceuticals, Inc. compare | n/m |
| NRXP NRx Pharmaceuticals, Inc. | n/m |
| OKUR OnKure Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)